论文部分内容阅读
目的观察芪参益气滴丸对慢性缺血性心肌病合并心力衰竭的临床疗效。方法纳入2011年4月～2011年10月我院收治的慢性缺血性心肌病伴心力衰竭患者84例,随机分为对照组(n=42)和治疗组(n=42)。对照组进行常规抗心衰治疗,治疗组在常规治疗的基础上联合应用芪参益气滴丸(0.5g,tid)。治疗2个月后观察两组心功能改善情况和血浆N-端脑钠肽前体(NT-proBNP)的变化。结果与对照组相比,治疗组患者6分钟步行试验距离较长[(427.0±26.8)mvs.(322.0±26.5)m]、左室射血分数(LVEF)较高[(51.6±2.9)%vs.(45.1±3.9)%]、NYHA分级改善明显(提高Ⅰ级以上:92.8%vs.73.8%),同时NT-proBNP水平更低[(1422±420)pg/mlvs.(2536±476)pg/ml]、差异均有统计学意义(P<0.05)。结论慢性缺血性心肌病心力衰竭在常规规范化治疗的基础上联合芪参益气滴丸治疗可明显改善心功能水平,获得较好的临床疗效。
Objective To observe the clinical effect of Qishen Yiqi drop pill on patients with chronic ischemic cardiomyopathy complicated with heart failure. Methods Eighty-four patients with chronic ischemic cardiomyopathy and heart failure admitted to our hospital from April 2011 to October 2011 were randomly divided into control group (n = 42) and treatment group (n = 42). The control group was given routine anti-heart failure treatment. The treatment group was treated with Qishen Yiqi Dripping Pills (0.5g, tid) on the basis of routine treatment. Two months after treatment, the improvement of cardiac function and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) were observed. Results Compared with the control group, the patients in the treatment group had a longer walking distance of 6 minutes [(427.0 ± 26.8) mvs. (322.0 ± 26.5) m] and higher LVEF (51.6 ± 2.9)% (45.1 ± 3.9)%], the NYHA classification improved significantly (more than grade Ⅰ: 92.8% vs.73.8%), while NT-proBNP level was lower [(1422 ± 420) pg / mlvs. pg / ml], the difference was statistically significant (P <0.05). Conclusion Heart failure in patients with chronic ischemic cardiomyopathy combined with Qishen Yiqi Dropping Pills can improve the level of cardiac function on the basis of routine standardized treatment and achieve better clinical efficacy.